ArticleSurgical case reports2025
An Extremely Rare Case of Coexisting Neuroendocrine Carcinoma and Tumor of the Whole Pancreas with Hepatoid Differentiation.
Article in Surgical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHepatoid carcinoma (HC) is a rare type of malignant tumor that shares similar serological, morphological, and immunohistochemical features with hepatocellular carcinoma. Pancreatic HC exhibits aggressive biological behavior and is classified as pure type, combined type, and mixed type. Unlike the pure type, the combined and mixed types refer to HC with other histological components. While the most common component is the neuroendocrine tumor (NET), no case of coexistence of neuroendocrine carcinoma (NEC) and NET with hepatoid differentiation has been reported. We herein report an extremely rare case of coexisting NEC and NET of the whole pancreas with hepatoid differentiation. CASE PRESENTATION: A 15-year-old woman had epigastric pain and impaired glucose tolerance, without any medical or family history. Computed tomography (CT) revealed a 6.4-cm mass in the pancreatic head, an enhanced mass throughout the pancreas, and a 1.0-cm liver lesion. Positron emission tomography (PET)/CT and somatostatin receptor scintigraphy (SRS) suggested a NET in the pancreatic body and tail, and a NEC in the pancreatic head. Biopsies confirmed NEC in the pancreatic head and liver with possible hepatoid differentiation. The patient underwent combination chemotherapy with carboplatin and etoposide. Due to the partial response achieved with chemotherapy, which led to significant tumor shrinkage on CT and no uptake on PET/CT in the pancreatic head tumor, the patient proceeded with conversion surgery, including a total pancreatectomy with portal vein resection and partial hepatectomy. However, serum α-fetoprotein (AFP) levels rapidly rose, and multiple liver metastases of NEC were detected on CT at 5 months after surgery. Liver metastases worsened despite further chemotherapy. The patient died 10 months after surgery.
conclusionsWe herein present an extremely rare case of coexisting NET and NEC of the whole pancreas with hepatoid differentiation. Due to a remarkable response to chemotherapy, conversion surgery was performed. However, early recurrence of liver metastases accompanied by a rapid increase in serum AFP levels occurred, and the prognosis was poor. Pancreatic HC should be considered when encountering a bulky tumor of the pancreas with elevated serum AFP levels, and further case series and analysis are needed to determine the appropriate treatment strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.